Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial

Stroke

Volumn 46, Issue 9, 2015, Pages 2523-2528

  Senoo, Keitaro ^a   Lip, Gregory Y H ^a,b   Lane, Deirdre A ^a   Büller, Harry R ^c   Kotecha, Dipak ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

atrial fibrillation; heart failure; mortality; stroke

Indexed keywords

ACENOCOUMAROL; CREATININE; IDRAPARINUX; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ADVERSE OUTCOME; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK; AGED; CHRONIC DISEASE; COMORBIDITY; EMBOLISM; MULTICENTER STUDY (TOPIC); PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; COMORBIDITY; EMBOLISM; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; STROKE;

EID: 84940426249     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.009487     Document Type: Article

References (32)

1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429. doi: 10.1093/eurheartj/ehq278.
2. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 2000;35:183-187.
3. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2015;36:281-27a. doi: 10.1093/eurheartj/ehu307.
4. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, et al; ROCKET-AF Steering Committee and Investigators. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J. 2015;36:288-296. doi: 10.1093/eurheartj/ehu359.
5. Lip GY, Frison L, Grind M; SPORTIF Investigators. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. J Intern Med. 2008;264:50-61. doi: 10.1111/j.1365-2796.2007.01909.x.
6. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013;34:2464-2471. doi: 10.1093/eurheartj/eht135.
7. Chiang CE, Naditch-Brûlé L, Murin J, Goethals M, Inoue H, O'Neill J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the reallife global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5:632-639. doi: 10.1161/CIRCEP.112.970749.
8. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747. doi: 10.1093/eurheartj/ehs253.
9. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269-e367. doi: 10.1161/CIR.0b013e318214876d.
10. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272. doi: 10.1378/chest.09-1584.
11. Kotecha D, Banerjee A, Lip GY. Increased stroke risk in atrial fibrillation patients with heart failure: does ejection fraction matter? Stroke. 2015;46:608-609. doi: 10.1161/STROKEAHA.114.008421.
12. Agarwal M, Apostolakis S, Lane DA, Lip GY. The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. Clin Ther. 2014;36:1135-1144. doi: 10.1016/j.clinthera.2014.07.015.
13. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al; Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235-2243. doi: 10.1016/S0140-6736(14)61373-8.
14. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32:695-703.
15. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920-2925. doi: 10.1161/01.CIR.0000072767.89944.6E.
16. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32:695-703.
17. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, et al; CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47:1997-2004. doi: 10.1016/j. jacc.2006.01.060.
18. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142-1147. doi: 10.1016/j.amjcard.2013.05.063.
19. AMADEUS Investigators, Bousser MG, Bouthier J, Buller HR, Cohen AT, Crijns H, et al
20. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012;60:861-867. doi: 10.1016/j.jacc.2012.06.019.
21. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213-220. doi: 10.2147/CLEP.S47385.
22. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. 2009;11:676-683. doi: 10.1093/eurjhf/hfp085.
23. Beuckelmann DJ, Näbauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation. 1992;85:1046-1055.
24. Ohkusa T, Ueyama T, Yamada J, Yano M, Fujumura Y, Esato K, et al. Alterations in cardiac sarcoplasmic reticulum Ca2+ regulatory proteins in the atrial tissue of patients with chronic atrial fibrillation. J Am Coll Cardiol. 1999;34:255-263.
25. Solti F, Vecsey T, Kékesi V, Juhász-Nagy A. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res. 1989;23:882-886.
26. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265-325. doi: 10.1152/physrev.00031.2009.
27. Taillandier S, Brunet Bernard A, Lallemand B, Simeon E, Pericart L, Clementy N, et al. Prognosis in patients hospitalized with permanent and nonpermanent atrial fibrillation in heart failure. Am J Cardiol. 2014;113:1189-1195. doi: 10.1016/j.amjcard.2013.12.024.
28. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al; European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422-2434. doi: 10.1093/eurheartj/ehi505.
29. Waldo AL, Becker RC, Tapson VF, Colgan KJ; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46:1729-1736. doi: 10.1016/j.jacc.2005.06.077.
30. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010;31:967-975. doi: 10.1093/eurheartj/ehn599.
31. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137:263-272. doi: 10.1378/chest.09-1584.
32. Sandhu RK, Hohnloser SH, Pfeffer MA, Yuan F, Hart RG, Yusuf S, et al. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. Stroke. 2015;46:667-672. doi: 10.1161/STROKEAHA.114.007140.